Symeres Overview

  • Year Founded
  • 1987

Year Founded

  • Status
  • Private

  • Employees
  • 600

Employees

  • Latest Deal Type
  • Buyout/​LBO

  • Financing Rounds
  • 3

  • Investments
  • 8

Symeres General Information

Description

Operator of a contract research organization intended to accelerate the drug discovery and development process. The company's services include medicinal chemistry, parallel chemistry, pre-formulation and process research, enabling clients to make better decisions regarding their projects.

Contact Information

Website
www.symeres.com
Formerly Known As
Mercachem, MercachemSyncom, Syncom
Ownership Status
Privately Held (backing)
Financing Status
Private Equity-Backed
Corporate Office
  • Kerkenbos 1013
  • 6546 BB Nijmegen
  • Netherlands
+31 024
Primary Industry
BPO/Outsource Services
Other Industries
Other Pharmaceuticals and Biotechnology
Drug Discovery
Vertical(s)
Life Sciences
Corporate Office
  • Kerkenbos 1013
  • 6546 BB Nijmegen
  • Netherlands
+31 024

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Symeres Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Symeres‘s full profile, request access.

Request a free trial

Symeres Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a contract research organization intended to accelerate the drug discovery and development process. The comp
BPO/Outsource Services
Nijmegen, Netherlands
600 As of 2025

Raleigh, NC
 

Nottingham, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Symeres Competitors (9)

One of Symeres’s 9 competitors is Parexel International, a Private Equity-Backed company based in Raleigh, NC.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Parexel International Private Equity-Backed Raleigh, NC
Sygnature Discovery Private Equity-Backed Nottingham, United Kingdom
Biorasi Private Equity-Backed Aventura, FL
Crown Bioscience Formerly VC-backed San Diego, CA
Zephyr AI Venture Capital-Backed McLean, VA
You’re viewing 5 of 9 competitors. Get the full list »

Symeres Patents

  • 52

    Total Documents Applications and Grants

  • Total Patents Families

  • 35

    Granted

  • Pending

  • Expiring in next 12 mo

Symeres Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240059672-A1 Method of preparing pralsetinib Active 04-Dec-2020
US-20220163539-A1 Nlrp3 inflammasome inhibition Inactive 12-Apr-2019
US-20220106289-A1 Nlrp3 inhibitors Inactive 23-Nov-2018
US-20220194923-A1 Novel sulfonamideurea compounds Active 15-Aug-2018
US-12187702-B2 Sulfonamideurea compounds Active 15-Aug-2018 C07D401/12
To view Symeres’s complete patent history, request access »

Symeres Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Symeres Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Symeres‘s full profile, request access.

Request a free trial

Symeres Investments & Acquisitions (8)

Symeres’s most recent deal was a Buyout/LBO with DGr Pharma. The deal was made on 10-Sep-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
DGr Pharma 10-Sep-2025 Buyout/LBO Consulting Services (B2B)
Oncolines 10-Jan-2023 Buyout/LBO BPO/Outsource Services
Exemplify Biopharma 25-Oct-2022 Buyout/LBO Other Pharmaceuticals and Biotechnology
Organix (Other Healthcare Services) 26-Apr-2022 Buyout/LBO Other Healthcare Services
Admescope 09-Nov-2020 Buyout/LBO Other Pharmaceuticals and Biotechnology
You’re viewing 5 of 8 investments and acquisitions. Get the full list »

Symeres Affiliates

Subsidiaries (6)

Name Industry Location Year Founded
Oncolines Oss, Netherlands 2021
DGr Pharma Breda, Netherlands 2018
Exemplify Biopharma Cranbury, NJ 2015
Admescope Oulu, Finland 2011
Syncom (Netherlands) Groningen, Netherlands 1988
You’re viewing 5 of 6 affiliates. Get the full list.  »

Symeres FAQs

  • When was Symeres founded?

    Symeres was founded in 1987.

  • Where is Symeres headquartered?

    Symeres is headquartered in Nijmegen, Netherlands.

  • What is the size of Symeres?

    Symeres has 600 total employees.

  • What industry is Symeres in?

    Symeres’s primary industry is BPO/Outsource Services.

  • Is Symeres a private or public company?

    Symeres is a Private company.

  • What is Symeres’s current revenue?

    The current revenue for Symeres is .

  • Who are Symeres’s investors?

    Keensight Capital has invested in Symeres.

  • Who are Symeres’s competitors?

    Parexel International, Sygnature Discovery, Biorasi, Crown Bioscience, and Zephyr AI are some of the 9 competitors of Symeres.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process